AstraZeneca Looks To Take On GSK And Merck In Endometrial Cancer With Imfinzi Nod

The FDA has approved the UK firm's checkpoint inhibitor to treat patients whose cancer is mismatch repair deficient (dMMR). The next challenge is to have a treatment for the remaining 70-80% of endometrial cancer patients with mismatch repair proficient (pMMR) disease.